Pipelines

Biogen value drops by $18bn after Alzheimer’s drug failure

21-Mar-2019 By Ben Hargreaves

Biogen and its partner, Eisai, confirm a decision to stop the Phase III development of aducanumab, a potential treatment for Alzheimer’s – a key part of the former’s pipeline.

WuXi Biologics becomes first Chinese EU approved CDMO

20-Mar-2019 By Ben Hargreaves

WuXi Biologics receives EMA GMP certification for the production of Trogarzo at its manufacturing facilities in Wuxi city and Shanghai, China.

Abzena tapped as CMC for Lipum’s biologic development project

20-Mar-2019 By Maggie Lynch

Abzena and Lipum enter agreement for the development of biologics for juvenile idiopathic arthritis, using the former’s proprietary cell line and GMP resources.

Takeda’s plasma manufacturing facility approved by FDA

20-Mar-2019 By Maggie Lynch

US FDA approves Takeda’s acquired plasma manufacturing facility in Georgia, US, for the production of flexbumin 25% solution.

Technology boosts access to biologics and insulin via oral delivery

18-Mar-2019 By Maggie Lynch

Drug delivery of biologics takes a sharp turn, as the development of pills that can replace injections and increase drug accessibility moves forward.

Cellectis to build CAR-T manufacturing sites in US and Europe

14-Mar-2019 By Ben Hargreaves

In a step towards the commercialisation of its ‘off-the-shelf’ CAR-T therapies, Cellectis begins construction of a facility in France and enters lease agreement for US facility.

NEWS IN BRIEF

Sagent acquires US facility with an eye on future biosimilar products

12-Mar-2019 By Staff reporter

Sagent purchases Xellia’s FDA-approved site in North Carolina, which has capabilities to manufacture both small molecule and biologic products.

Fujifilm continues ‘aggressive’ expansion with $890m site purchase

12-Mar-2019 By Ben Hargreaves

Fujifilm continues investment in its manufacturing capabilities through the acquisition of a large-scale biologics site from Biogen.

‘Can you manufacture consistently?’ The big question in regenerative medicine

11-Mar-2019 By Ben Hargreaves

Regenerative medicine raised $13.3bn in funds during 2018 but investors question whether treatments can be manufactured consistently, according to AMR annual report.

Kite collaborates to increase efficiency of CAR-T manufacture

07-Mar-2019 By Ben Hargreaves

MaxCyte announces a partnership with Kite to explore the use of flow electroporation technology to enable the non-viral cell engineering of CAR-T drug candidates.

Krystal moves towards ‘full integration’ with gene therapy facility opening

07-Mar-2019 By Ben Hargreaves

Krystal opens cGMP facility for the clinical and commercial manufacture of its lead drug candidate, KB103, and plans to open its second in 2020.

$4bn collaboration sees Abpro expand its global capabilities

07-Mar-2019 By Maggie Lynch

Abpro and NJCTTQ enter $4bn agreement to develop bispecific antibody therapies for immuno-oncology and extend its global reach.

Nightstar acquired by Biogen for $800m

05-Mar-2019 By Maggie Lynch

Biogen agrees Nightstar acquisition for $800m to take on its pipeline of AAV treatments for retinal disorders, diversifyingy its pipeline in the rare disease market.

ABL extends antibody agreement in $220m deal with WuXi Biologics

27-Feb-2019 By Maggie Lynch

ABL will use WuXi’s platforms in an extended agreement for the development and commercialization of its bispecific antibodies, using the recently launched WuXiBody platform.